Entrada Therapeutics presents new data on expanding Duchenne Franchise
PremiumThe FlyEntrada Therapeutics presents new data on expanding Duchenne Franchise
1M ago
Entrada promotes Sethuraman to President of Research, Development
Premium
The Fly
Entrada promotes Sethuraman to President of Research, Development
2M ago
Entrada Therapeutics reports Q2 EPS $1.55, consensus 14c
Premium
The Fly
Entrada Therapeutics reports Q2 EPS $1.55, consensus 14c
3M ago
Two new option listings on May 30th
PremiumThe FlyTwo new option listings on May 30th
5M ago
Entrada Therapeutics reports Q1 EPS 68c, consensus (59c)
Premium
The Fly
Entrada Therapeutics reports Q1 EPS 68c, consensus (59c)
6M ago
Entrada Therapeutics expects cash to fund requirements through 2Q26
Premium
The Fly
Entrada Therapeutics expects cash to fund requirements through 2Q26
8M ago
Entrada Therapeutics price target lowered to $20 from $25 at H.C. Wainwright
PremiumThe FlyEntrada Therapeutics price target lowered to $20 from $25 at H.C. Wainwright
12M ago
Entrada completes dosing for first, second cohorts Phase 1 ENTR-601-44-101
Premium
The Fly
Entrada completes dosing for first, second cohorts Phase 1 ENTR-601-44-101
12M ago
Entrada Therapeutics expects cash to fund requirements through 2025
Premium
The Fly
Entrada Therapeutics expects cash to fund requirements through 2025
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100